Objectives: The study was undertaken to evaluate the release kinetics
of cardiac troponin I (cTn-I) in ischemic myocardial injury. Design an
d Methods: The reference range for cTn-I was established by determinat
ion of cTn-I in sera and plasma obtained from 622 healthy volunteers (
Group 1). cTn-I was compared to: (a) Creatine kinase (CK) MB mass and
myoglobin in 12 patients with severe skeletal muscle damage (Group 2);
(b) CK-MB activity in 48 patients with myocardial infarction (MI) rec
eiving intravenous thrombolysis (Group 3) (in this group, an additiona
l 43 patients with MI were analyzed separately to characterize cTn-I p
atterns in thrombolyzed and nonthrombolyzed populations); and in 44 pa
tients with unstable angina (Group 4). Results: in Groups 1 and 2, no
positive results (greater than or equal to 0.1 mu g/L) were obtained.
In Group 3, the time-courses of cTn-I were mostly monophasic in form.
A pathologic increase occurred earlier in cTn-I than in CK-MB activity
(p = 0.0002); the period with increased cTn-I was longer (p = 0.001),
the overall sensitivity of cTn-I (93.9%) was higher than that of CK-M
B activity (p = 0.00001). cTn-I was more sensitive at admission (p = 0
.0004). In additional patients, the cTn-I peak occurred and cTn-I disa
ppeared significantly later in nonthrombolyzed than in the thrombolyze
d group. In Group 4, positive tests results were detected in 45% of pa
tients for cTn-I, 16% for CK-MB activity, and 32% for CK-MB mass. Conc
lusions: The cTn-I assay appears to be ideally suited for the detectio
n of ischemic myocardial injury in complex clinical situations because
of its high specificity; cTn-I indicates myocardial tissue damage in
patients with unstable angina and is superior to CK-MB activity and ma
ss in this respect.